menu
    • menu
    [{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ono Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"National Cancer Centre, Singapore","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Centre, Singapore","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Centre, Singapore \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Centre, Singapore \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Medigen Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medigen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigen Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medigen Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tegafur","moa":"||RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Taiho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nordic Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tegafur","moa":"||RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Nordic Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nordic Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nordic Pharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Tegafur

    Menu

    Tegafur

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Medigen Biotechnology

                            Taiwan arrow
                            FNCE
                            Not Confirmed

                            Medigen Biotechnology

                            Taiwan arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tegafur

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase I/II Study: Allogeneic NK-cell Therapy with Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Pati...

                            Details : Tegafur is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Pancreatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 12, 2024

                            Lead Product(s) : Tegafur

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            National Cancer Centre, Singapore

                            Country arrow
                            FNCE
                            Not Confirmed

                            National Cancer Centre, Singapore

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tegafur

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Taiho Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

                            Details : Tegafur is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 17, 2023

                            Lead Product(s) : Tegafur

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Taiho Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Taiho Pharmaceutical

                            Japan arrow
                            FNCE
                            Not Confirmed

                            Taiho Pharmaceutical

                            Japan arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tegafur,Gimeracil

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Taiho Pharmaceutical Obtains Additional Indication of "Postoperative Adjuvant Chemotherapy for Hormone Recepto...

                            Details : TS-1 is a combination of three pharmacological compounds: tegafur, an antimetabolite agent that, after absorption by the gastrointestinal tract, is converted into the anticancer agent fluorouracil (5-FU); gimeracil (5-chloro-2, 4-dihydroxypyridine, or CD...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 24, 2022

                            Lead Product(s) : Tegafur,Gimeracil

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nordic Pharma

                            France arrow
                            FNCE
                            Not Confirmed

                            Nordic Pharma

                            France arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tegafur,Gimeracil,Oteracil

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Positive EMA Opinion for the Use of Teysuno in Metastatic Colorectal Cancer

                            Details : Based on the positive opinion from EMA, Teysuno (Tegafur) an oral fluoropyrimidine will be indicated in adults for the treatment of advanced gastric cancer when given in combination with cisplatin.

                            Product Name : Teysuno

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 04, 2022

                            Lead Product(s) : Tegafur,Gimeracil,Oteracil

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ono Pharmaceutical

                            Japan arrow
                            FNCE
                            Not Confirmed

                            Ono Pharmaceutical

                            Japan arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nivolumab,Oxaliplatin,Tegafur

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ONO Submits Supplemental Application for Approval for Opdivo® to Expand the Use in Recurrent Gastric Cancer

                            Details : The supplemental application for approval for Opdivo® has been filed based on the data from the following 2 clinical studies: CheckMate -649 study (ONO-4538-44) and ATTRACTION-4 study (ONO-4538-37.

                            Product Name : Opdivo

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            December 10, 2020

                            Lead Product(s) : Nivolumab,Oxaliplatin,Tegafur

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth